FOLD vs. GERN, MDGL, ALKS, PRGO, DVAX, LGND, IRWD, BBIO, MNKD, and OPK
Should you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Geron (GERN), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Perrigo (PRGO), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD), BridgeBio Pharma (BBIO), MannKind (MNKD), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
Amicus Therapeutics (NASDAQ:FOLD) and Geron (NASDAQ:GERN) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk and media sentiment.
Amicus Therapeutics currently has a consensus price target of $20.00, indicating a potential upside of 92.31%. Geron has a consensus price target of $6.10, indicating a potential upside of 55.22%. Given Amicus Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Amicus Therapeutics is more favorable than Geron.
Amicus Therapeutics has a net margin of -37.96% compared to Geron's net margin of -38,730.00%. Geron's return on equity of -72.19% beat Amicus Therapeutics' return on equity.
Amicus Therapeutics has higher revenue and earnings than Geron. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.
Amicus Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
In the previous week, Geron had 26 more articles in the media than Amicus Therapeutics. MarketBeat recorded 31 mentions for Geron and 5 mentions for Amicus Therapeutics. Geron's average media sentiment score of 0.37 beat Amicus Therapeutics' score of -0.05 indicating that Geron is being referred to more favorably in the news media.
73.7% of Geron shares are owned by institutional investors. 2.1% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Amicus Therapeutics received 33 more outperform votes than Geron when rated by MarketBeat users. Likewise, 73.46% of users gave Amicus Therapeutics an outperform vote while only 69.52% of users gave Geron an outperform vote.
Summary
Amicus Therapeutics and Geron tied by winning 9 of the 18 factors compared between the two stocks.
Get Amicus Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amicus Therapeutics Competitors List
Related Companies and Tools
